ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
02 Mayo 2024 - 3:05PM
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announced it will present
novel research and exhibit at the 27th American Society of Gene
& Cell Therapy Annual Meeting to be held in Baltimore, MD from
May 7-11.
The following original research abstracts will be presented at
the Poster Session:
- De-Risking Clinical Trials Leveraging
MRI-Guided Intraparenchymal Delivery by Validating Commercially
Available Infusion Pumps for Gene and Cell Therapy Infusions
- Intraparenchymal Infusions to Deep
Brain Structures Using Low Field MRI (in collaboration with The
Ohio State University Wexner Medical Center)
Additionally, the Company’s technology will be featured in
multiple partner posters and presentations. Conference attendees
may visit the ClearPoint Neuro booth, #1033, to obtain a
comprehensive list. Attendees may also pre-book meetings with our
team directly here.
“The ASGCT Annual Meeting provides an extraordinary opportunity
for us to connect with our existing partners, and attract potential
new customers,” stated Jeremy Stigall, Chief Business Officer at
ClearPoint Neuro. “This year, in addition to the posters listed
above, there are more than 10 partner-authored abstracts that are
enabled by ClearPoint Neuro innovations.”
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling
company offering precise navigation to the brain and spine. The
Company uniquely provides both established clinical products as
well as pre-clinical development services for controlled drug and
device delivery. The Company’s flagship product, the ClearPoint
Neuro Navigation System, has FDA clearance and is CE-marked.
ClearPoint Neuro is engaged with healthcare and research centers in
North America, Europe, Asia, and South America. The Company is also
partnered with the most innovative pharmaceutical/biotech
companies, academic centers, and contract research organizations,
providing solutions for direct CNS delivery of therapeutics in
pre-clinical studies and clinical trials worldwide. To date,
thousands of procedures have been performed and supported by the
Company’s field-based clinical specialist team, which offers
support and services to our customers and partners worldwide. For
more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the context of the federal securities laws, which
may include the Company’s expectations for the future performance,
market, and revenue of its products and services. These
forward-looking statements are based on management’s current
expectations and are subject to the risks inherent in the business,
which may cause the Company's actual results to differ materially
from those expressed in or implied by forward-looking statements.
Particular uncertainties and risks include those relating to:
global and political instability, supply chain disruptions, labor
shortages, and macroeconomic and inflationary conditions; future
revenue from sales of the Company’s products and services; the
Company’s ability to market, commercialize and achieve broader
market acceptance for new products and services offered by the
Company; the ability of our biologics and drug delivery partners to
achieve commercial success, including their use of the Company’s
products and services in their delivery of therapies; the Company’s
expectations, projections and estimates regarding expenses, future
revenue, capital requirements, and the availability of and the need
for additional financing; the Company’s ability to obtain
additional funding to support its research and development
programs; the ability of the Company to manage the
growth of its business; the Company’s ability to attract and retain
its key employees; and risks inherent in the research, development,
and regulatory approval of new products. More detailed information
on these and additional factors that could affect the Company’s
actual results are described in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, which has been filed with the Securities and Exchange
Commission, and the Company’s Quarterly Report on Form 10-Q for the
three months ended March 31, 2024, which the Company intends to
file with the Securities and Exchange Commission on or before May
15, 2024. The Company does not assume any obligation to update
these forward-looking statements.
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ClearPoint Neuro (NASDAQ:CLPT)
Gráfica de Acción Histórica
De May 2023 a May 2024